166 related articles for article (PubMed ID: 21130043)
1. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
Tvorogov D; Anisimov A; Zheng W; Leppänen VM; Tammela T; Laurinavicius S; Holnthoner W; Heloterä H; Holopainen T; Jeltsch M; Kalkkinen N; Lankinen H; Ojala PM; Alitalo K
Cancer Cell; 2010 Dec; 18(6):630-40. PubMed ID: 21130043
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
3. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
4. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.
Alam A; Herault JP; Barron P; Favier B; Fons P; Delesque-Touchard N; Senegas I; Laboudie P; Bonnin J; Cassan C; Savi P; Ruggeri B; Carmeliet P; Bono F; Herbert JM
Biochem Biophys Res Commun; 2004 Nov; 324(2):909-15. PubMed ID: 15474514
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic regeneration: new insights from VEGFR-3 blockade.
Aoki Y; Tosato G
J Natl Cancer Inst; 2005 Jan; 97(1):2-3. PubMed ID: 15632367
[No Abstract] [Full Text] [Related]
7. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Simiantonaki N; Jayasinghe C; Michel-Schmidt R; Peters K; Hermanns MI; Kirkpatrick CJ
Int J Oncol; 2008 Mar; 32(3):585-92. PubMed ID: 18292935
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
9. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
10. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
16. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
17. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.
Witmer AN; Blaauwgeers HG; Weich HA; Alitalo K; Vrensen GF; Schlingemann RO
Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):849-57. PubMed ID: 11867607
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
[TBL] [Abstract][Full Text] [Related]
20. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
Nykänen AI; Sandelin H; Krebs R; Keränen MA; Tuuminen R; Kärpänen T; Wu Y; Pytowski B; Koskinen PK; Ylä-Herttuala S; Alitalo K; Lemström KB
Circulation; 2010 Mar; 121(12):1413-22. PubMed ID: 20231530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
